

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

 **PREVYMIS®**

letermovir tablets

Tablets, 240 mg and 480 mg, oral

letermovir for injection

Solution for injection, 20 mg/mL, 240 mg/vial and 480 mg/vial, intravenous

Antiviral Agent

Merck Canada Inc.  
16750 route Transcanadienne  
Kirkland QC Canada H9H 4M7  
[www.merck.ca](http://www.merck.ca)

Date of Initial Authorization:  
November 1, 2017

Date of Revision:  
September 21, 2023

Submission Control Number: 272553

## RECENT MAJOR LABEL CHANGES

1 INDICATIONS	09/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment	09/2023
7 WARNINGS AND PRECAUTIONS	09/2023

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

<b>RECENT MAJOR LABEL CHANGES</b>	<b>2</b>
<b>TABLE OF CONTENTS</b>	<b>2</b>
<b>PART I: HEALTH PROFESSIONAL INFORMATION</b>	<b>4</b>
<b>1 INDICATIONS</b>	<b>4</b>
1.1 Pediatrics	4
1.2 Geriatrics	4
<b>2 CONTRAINDICATIONS</b>	<b>4</b>
<b>4 DOSAGE AND ADMINISTRATION</b>	<b>5</b>
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment	5
4.3 Reconstitution	6
4.4 Administration	8
4.5 Missed Dose	9
<b>5 OVERDOSAGE</b>	<b>9</b>
<b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</b>	<b>9</b>
<b>7 WARNINGS AND PRECAUTIONS</b>	<b>10</b>
7.1 Special Populations	12
7.1.1 Pregnant Women	12
7.1.2 Breast-feeding	12
7.1.3 Pediatrics	12
7.1.4 Geriatrics	12
<b>8 ADVERSE REACTIONS</b>	<b>12</b>
8.1 Adverse Reaction Overview	12
8.2 Clinical Trial Adverse Reactions	13

8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	14
8.5	Post-Market Adverse Reactions.....	15
<b>9</b>	<b>DRUG INTERACTIONS .....</b>	<b>15</b>
9.1	Serious Drug Interactions .....	15
9.2	Drug Interactions Overview .....	16
9.4	Drug-Drug Interactions .....	16
9.5	Drug-Food Interactions.....	27
9.6	Drug-Herb Interactions .....	27
9.7	Drug-Laboratory Test Interactions.....	27
<b>10</b>	<b>CLINICAL PHARMACOLOGY.....</b>	<b>27</b>
10.1	Mechanism of Action .....	27
10.2	Pharmacodynamics.....	27
10.3	Pharmacokinetics.....	27
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL.....</b>	<b>31</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS.....</b>	<b>31</b>
	<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>32</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION .....</b>	<b>32</b>
<b>14</b>	<b>CLINICAL TRIALS .....</b>	<b>32</b>
14.1	Clinical Trials by Indication .....	32
	Adult CMV-seropositive Recipients [R+] of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT): .....	32
	Adult CMV-seronegative Recipients of a Kidney Transplant from a CMV-seropositive Donor [D+/R-].....	35
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>39</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>40</b>
	<b>PATIENT MEDICATION INFORMATION .....</b>	<b>42</b>

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

PREVYMIS® (letermovir) is indicated for:

- the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
- the prophylaxis of CMV disease in adult kidney transplant recipients who are at high risk (donor CMV-seropositive [D+]/recipient CMV-seronegative [R-]).

#### 1.1 Pediatrics

**Pediatrics (< 18 years of age):** No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

#### 1.2 Geriatrics

**Geriatrics (≥ 65 years of age):** Safety and efficacy were similar across older and younger subjects in the Phase 3 trials in HSCT recipients and in the Phase 3 trial in kidney transplant recipients.

### 2 CONTRAINDICATIONS

PREVYMIS® is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

#### **Pimozide**

Concomitant administration of PREVYMIS® may result in increased concentrations of pimozide due to inhibition of cytochrome P450 3A (CYP3A) by letermovir, leading to QT prolongation and torsades de pointes (see [7 WARNINGS AND PRECAUTIONS](#) and [9.2 Drug Interactions Overview](#)).

#### **Ergot Alkaloids**

Concomitant administration of PREVYMIS® may result in increased concentrations of ergot alkaloids (ergotamine and dihydroergotamine) due to inhibition of CYP3A by letermovir, which may lead to ergotism (see [7 WARNINGS AND PRECAUTIONS](#) and [9.2 Drug Interactions Overview](#)).

#### **Cyclosporine with lovastatin, rosuvastatin or simvastatin**

Concomitant administration of PREVYMIS® when used in combination with cyclosporine is contraindicated as it may result in significantly increased lovastatin, rosuvastatin or simvastatin concentrations, which may lead to myopathy or rhabdomyolysis (see [7 WARNINGS AND PRECAUTIONS](#) and [9.2 Drug Interactions Overview](#)).

#### **Cyclosporine with bosentan**

Concomitant administration of PREVYMIS® when used in combination with cyclosporine is contraindicated as it may result in significantly increased concentrations of bosentan (see [7 WARNINGS AND PRECAUTIONS](#) and [9.2 Drug Interactions Overview](#)).

## 4 DOSAGE AND ADMINISTRATION

### 4.1 Dosing Considerations

#### PREVYMIS® Tablets

- Administer with or without food.
- Swallow tablets whole. Do not divide, crush or chew.

#### PREVYMIS® Injection

- PREVYMIS® injection must be administered through a sterile 0.2 micron or 0.22 micron polyethersulfone (PES) in-line filter.
- Do not administer as an IV bolus injection.
- Administer by intravenous (IV) infusion upon dilution via a peripheral catheter or central venous line over approximately 60 minutes.

PREVYMIS® tablet and injection may be used interchangeably at the discretion of the physician, and no dose adjustment is necessary.

### 4.2 Recommended Dose and Dosage Adjustment

#### Recommended Dosage

##### Adults:

The recommended dosage of PREVYMIS® is 480 mg administered once daily.

If PREVYMIS® is co-administered with cyclosporine, the dosage of PREVYMIS® should be decreased to 240 mg once daily (see Dosage Adjustment in Adults section below).

##### HSCT

PREVYMIS® should be started after HSCT. PREVYMIS® may be started on the day of transplant and no later than 28 days post-HSCT. PREVYMIS® may be started before or after engraftment. Continue PREVYMIS® through 100 days post-HSCT.

##### Kidney Transplant

PREVYMIS® should be started on the day of transplant and no later than 7 days post-kidney transplant and continued through 200 days post-transplant.

##### **Pediatrics (< 18 years of age):**

Safety and efficacy of PREVYMIS® have not been established in pediatric patients less than 18 years of age.

##### **Geriatrics (≥ 65 years of age):**

No dose adjustment of PREVYMIS® is required based on age (see [10.3 Pharmacokinetics](#)).

### **Dosage Adjustment in Adults**

If PREVYMIS® is co-administered with cyclosporine, the dosage of PREVYMIS® should be decreased to 240 mg once daily (see [4.3 Reconstitution](#), [9 DRUG INTERACTIONS](#) and [10.3 Pharmacokinetics](#)).

- If cyclosporine is initiated after starting PREVYMIS®, the next dose of PREVYMIS® should be decreased to 240 mg once daily.
- If cyclosporine is discontinued after starting PREVYMIS®, the next dose of PREVYMIS® should be increased to 480 mg once daily.
- If cyclosporine dosing is temporarily interrupted due to high cyclosporine levels, no dose adjustment of PREVYMIS® is needed.

### **Renal Impairment**

No dose adjustment of PREVYMIS® is required based on renal impairment (see [Renal, Combined Renal and Hepatic Insufficiency](#) and [10.3 Pharmacokinetics](#)).

### **Hepatic Impairment**

No dose adjustment of PREVYMIS® is required based on mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment. PREVYMIS® is not recommended for patients with severe (Child-Pugh Class C) hepatic impairment (see [Hepatic/Biliary/Pancreatic, Combined Renal and Hepatic Insufficiency](#) and [10.3 Pharmacokinetics](#)).

### **Combined Renal and Hepatic Impairment**

PREVYMIS® is not recommended in patients with moderate hepatic impairment combined with moderate or severe renal impairment (CrCl less than 50 mL/min) (see [Combined Renal and Hepatic Insufficiency](#) and [10.3 Pharmacokinetics](#)).

## **4.3 Reconstitution**

### **Parenteral Products:**

- Add one single-dose vial of PREVYMIS® injection to a 250 mL pre-filled IV bag containing either 0.9% sodium chloride injection or 5% dextrose injection and mix bag gently. Do not shake.
- Once diluted, the solution of PREVYMIS® is clear, and ranges from colorless to yellow. Variations of color within this range do not affect the quality of the product. The diluted solution should be inspected visually for particulate matter and discoloration prior to administration.
- Discard if the diluted solution is cloudy, discolored, or contains matter other than a few small translucent or white particles.

### Storage of Diluted Solution

- The diluted solution can be stored for up to 24 hours at room temperature or up to 48 hours under refrigeration at 2°C to 8°C.
- This time includes storage of the diluted solution in the IV bag through the duration of infusion.

### **Compatible Diluents, Drug Products, and Other Materials Used for Intravenous Administration**

#### Compatible Diluents

PREVYMIS® injection is compatible with 0.9% sodium chloride injection and 5% dextrose injection.

#### Compatible Drug Products

A study was conducted to evaluate physical compatibility of PREVYMIS® injection with injectable drug products. Compatibility was determined through visual observations, turbidity, and measurement of particulate matter. Compatible drug products are listed below.

PREVYMIS® should not be co-administered through the same IV line (or cannula) with other drug products and diluent combinations except those listed below.

**The following compatible drug products<sup>†</sup> may be co-administered with PREVYMIS® for injection when both drug products are in 0.9% Sodium Chloride via Y tubing only, as per the approved instructions of the respective drug products.**

- Ampicillin sodium
- Anti-thymocyte globulin
- Caspofungin
- Daptomycin
- Fentanyl citrate
- Fluconazole
- Furosemide
- Human insulin
- Magnesium sulfate
- Methotrexate
- Micafungin

<sup>†</sup> These injectable drug products are available in Canada

**The following compatible drug products<sup>†</sup> may be co-administered with PREVYMIS® for injection when both drug products are in 5% Dextrose via Y tubing only, as per the approved instructions of the respective drug products.**

- Amphotericin B (lipid complex)<sup>#</sup>
- Anidulafungin
- Cefazolin sodium
- Ceftriaxone sodium
- Famotidine
- Folic acid
- Ganciclovir sodium
- Hydrocortisone sodium succinate
- Morphine sulfate
- Norepinephrine bitartrate
- Pantoprazole sodium
- Potassium chloride
- Potassium phosphate
- Tacrolimus
- Telavancin
- Tigecycline

† These injectable drug products are available in Canada

# Amphotericin B (lipid complex) is compatible with PREVYMIS®. However, Amphotericin B (liposomal) is incompatible (see below Incompatible Drug Products and Other Materials Used for Intravenous Administration).

#### Compatible IV Bags and Infusion Set Materials

PREVYMIS® is compatible with the following IV bags and infusion set materials. Any IV bags or infusion set materials not listed below should not be used.

#### IV Bags Materials:

Polyvinyl chloride (PVC), ethylene vinyl acetate (EVA) and polyolefin (polypropylene and polyethylene)

#### Infusion Sets Materials:

PVC, polyethylene (PE), polybutadiene (PBD), silicone rubber (SR), styrene–butadiene copolymer (SBC), styrene-butadiene-styrene copolymer (SBS), polystyrene (PS)

#### Plasticizers:

Tris (2-ethylhexyl) trimellitate (TOTM), butyl benzyl phthalate (BBP)

#### Catheters:

Radiopaque polyurethane

### **Incompatible Drug Products and Other Materials Used for Intravenous Administration**

#### Incompatible Drug Products

PREVYMIS® injection is physically incompatible with amiodarone HCl, amphotericin B (liposomal), aztreonam, cefepime HCl, ciprofloxacin, cyclosporine, diltiazem HCl, filgrastim, gentamicin sulfate, levofloxacin, linezolid, lorazepam, midazolam HCl, mycophenolate mofetil HCl, ondansetron, and palonosetron.

#### Incompatible IV Bags and Infusion Set Materials

PREVYMIS® injection is incompatible with diethylhexyl phthalate (DEHP) plasticizers and polyurethane-containing IV administration set tubing.

### **4.4 Administration**

PREVYMIS® injection is supplied in 30 mL single-dose vials containing either 240 mg (12 mL per vial) or 480 mg (24 mL per vial). The preparation and administration instructions are the same for either dose.

PREVYMIS® vials are for single use only. Discard any unused portion.

- The diluted solution must be administered through a sterile 0.2 micron or 0.22 micron PES in-line filter.
- Do not administer the diluted solution through a filter other than a sterile 0.2 micron or 0.22 micron PES in-line filter.
- Administer as an IV infusion upon dilution only. Do not administer as an IV push or bolus.



- After dilution, administer PREVYMIS® via IV infusion via peripheral or central venous catheter using a total time of approximately 60 minutes. Administer the entire contents of the IV bag.

#### Preparation

- PREVYMIS® must be diluted prior to IV use.
- Inspect vial contents for discoloration and particulate matter prior to dilution. PREVYMIS® injection is a clear colorless solution and may contain a few product-related small translucent or white particles.
- Do not use the vial if the solution is cloudy, discolored, or contains matter other than a few small translucent or white particles.
- Do not use PREVYMIS® injection with IV bags and infusion set materials containing polyurethane or the plasticizer diethylhexyl phthalate (DEHP). Materials that are phthalate-free are also DEHP-free.
- Do not shake PREVYMIS® vial.

#### **4.5 Missed Dose**

Instruct patients that if they miss a dose of PREVYMIS®, they should take it as soon as they remember. If they do not remember until it is time for the next dose, instruct them to skip the missed dose and go back to the regular schedule. Instruct patients not to double their next dose or take more than the prescribed dose.

### **5 OVERDOSAGE**

During Phase 1 clinical trials, 86 healthy subjects received doses ranging from 720 mg/day to 1440 mg/day of PREVYMIS® for up to 14 days. The adverse reaction profile was similar to that of the clinical dose of 480 mg/day. There is no specific antidote for overdose with PREVYMIS®. In case of overdose, it is recommended that the patient be monitored for adverse reactions and appropriate symptomatic treatment instituted.

It is unknown whether dialysis will result in meaningful removal of PREVYMIS® from systemic circulation.

For management of a suspected drug overdose, contact your regional poison control centre.

### **6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**

**Table 1 – Dosage Forms, Strengths, Composition and Packaging**

<b>Route of Administration</b>	<b>Dosage Form / Strength/Composition</b>	<b>Non-medicinal Ingredients</b>
Oral	Tablet 240 mg, 480 mg	Colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and povidone 25.

		Film-coating: hypromellose 2910, iron oxide yellow, and (only for 480 mg tablets) iron oxide red, lactose monohydrate, titanium dioxide and triacetin. Carnauba wax is added as a polishing agent.
Intravenous infusion	Solution for Injection 20 mg / mL	Preservative-free sterile solution in single-dose vials of either 240 mg or 480 mg per vial. Each 1 mL of solution contains hydroxypropyl betadex (150 mg), sodium chloride (3.1 mg), sodium hydroxide (1.2 mg), and Water for Injection. The amount of sodium hydroxide may be adjusted to achieve a pH of approximately 7.5.

**Tablet:**

PREVMIS® 240 mg tablet is a yellow oval tablet. Each tablet is debossed with “591” on one side and Corporate logo on the other side. The 240 mg tablets are packaged in aluminum foil blister and lidding in cartons of 28 tablets.

PREVMIS® 480 mg tablet is a pink oval, bi-convex tablet. Each tablet is debossed with “595” on one side and Corporate logo on the other side. The 480 mg tablets are packaged in aluminum foil blister and lidding in cartons of 28 tablets.

**Solution for Injection:**

PREVMIS® for injection 240 mg/12 mL (20 mg/mL) is supplied in a single-dose vial.

PREVMIS® for injection 480 mg/24 mL (20 mg/mL) is supplied in a single-dose vial.

**7 WARNINGS AND PRECAUTIONS**

**General**

**Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions**

- The concomitant use of PREVMIS® and certain drugs may result in known or potentially significant drug interactions, some of which may lead to:
  - Possible clinically significant adverse reactions from greater exposure of concomitant drugs or PREVMIS®.
  - Significant decrease of concomitant drug plasma concentrations which may lead to reduced therapeutic effect of the concomitant drug.

See **Table 5** for steps to prevent or manage these known or potentially significant drug interactions, including dosing recommendations (see [2 CONTRAINDICATIONS](#), [9.2 Drug Interactions Overview](#) and [9.4 Drug-Drug Interactions](#)). Consider the potential for drug interactions prior to and during PREVMIS® therapy; review concomitant medications during PREVMIS® therapy; and monitor for the adverse reactions associated with the concomitant drugs.

PREVMIS® should be used with caution with drugs that are CYP3A substrates with narrow therapeutic ranges (e.g., alfentanil, fentanyl, and quinidine<sup>1</sup>) as co-administration may result in increases in the plasma concentrations of CYP3A substrates. Close monitoring and/or dose adjustment of co-

administered CYP3A substrates is recommended (see **Table 5**, [9.2 Drug Interactions Overview](#) and [9.4 Drug-Drug Interactions](#)).

Co-administration of PREVMIS® with strong and moderate inducers of transporters (e.g., P-gp) and/or enzymes (e.g. UGTs) is not recommended due to the potential for a decrease in letermovir plasma concentrations.

Rifampin co-administration resulted in an initial increase in letermovir plasma concentrations (due to OATP1B1/3 inhibition) that is not clinically significant, followed by clinically relevant decreases in letermovir plasma concentrations with continued rifampin co-administration. This may result in loss of prophylactic efficacy and necessitate initiation of anti-CMV therapy for CMV reactivation and/or disease.

Co-administration of PREVMIS® may result in increases in the plasma concentrations of cyclosporine, tacrolimus, and sirolimus. Close monitoring and/or dose adjustment of cyclosporine, tacrolimus, and sirolimus is recommended when co-administered with PREVMIS®.

### **Hepatic/Biliary/Pancreatic**

#### ***Hepatic Insufficiency***

Exposure to PREVMIS® is increased 1.6- to 3.8-fold in subjects with moderate and severe hepatic impairment. No dose adjustment of PREVMIS® is required based on mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment. PREVMIS® is not recommended for patients with severe (Child-Pugh Class C) hepatic impairment (see [4.2 Recommended Dose and Dosage Adjustment, Combined Renal and Hepatic Insufficiency](#) and [10.3 Pharmacokinetics](#)).

### **Renal**

#### ***Renal Insufficiency***

Exposure to PREVMIS® is increased 1.4- to 1.9-fold in subjects with moderate and severe renal impairment. No dose adjustment of PREVMIS® is required based on renal impairment (see [4.2 Recommended Dose and Dosage Adjustment, Combined Renal and Hepatic Insufficiency](#) and [10.3 Pharmacokinetics](#)). There are no data in patients with end-stage renal disease (CrCl less than 10 mL/min), including patients on dialysis.

In patients with moderate or severe renal impairment (CrCl less than 50 mL/min) receiving PREVMIS® injection, accumulation of the IV vehicle, hydroxypropyl betadex, could occur. Serum creatinine levels should be closely monitored in these patients.

#### ***Combined Renal and Hepatic Insufficiency***

PREVMIS® is not recommended in patients with moderate hepatic impairment combined with moderate or severe renal impairment (see [4.2 Recommended Dose and Dosage Adjustment](#) and [10.3 Pharmacokinetics](#)).

### **Reproductive Health: Female and Male Potential**

#### **• Fertility**

There were no effects on female fertility in rats. Impairment of fertility was observed in male rats, but not in male mice or male monkeys (see [16 NON-CLINICAL TOXICOLOGY](#)). Testicular toxicity in rats appears to be species-specific, and the relevance to humans is unknown. In the Phase 3 trials in HSCT and kidney transplant recipients, there was no evidence of letermovir-related testicular toxicity (see [8.2](#)

[Clinical Trials Adverse Reactions, 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data](#)).

## 7.1 Special Populations

### 7.1.1 Pregnant Women

No human data are available to establish whether or not PREVYMIS® poses a risk to pregnancy outcomes, therefore, the potential risk to humans is unknown. PREVYMIS® should not be used in pregnancy unless benefit outweighs the risk.

Embryofetal toxicity was observed in rats and rabbits at maternally toxic systemic AUC exposures of approximately 11- and 2-fold, respectively, the AUC at the recommended human dose (RHD). In the rat pre- and postnatal development study, no developmental toxicity was observed up to the highest maternal systemic AUC exposure (approximately 2-fold the AUC at the RHD).

In pregnant rats, letermovir was able to cross the placenta (see [10.3 Pharmacokinetics](#)).

### 7.1.2 Breast-feeding

It is not known whether letermovir is present in human breast milk, affects human milk production, or has effects on the breastfed child.

When administered to lactating rats, letermovir was present in milk, without effects on growth and development in nursing pups.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PREVYMIS® and any potential adverse effects on the breastfed child from PREVYMIS® or from the underlying maternal condition.

### 7.1.3 Pediatrics

**Pediatrics (< 18 years of age):** No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

### 7.1.4 Geriatrics

**Geriatrics (≥ 65 years of age):** Safety and efficacy were similar across older and younger subjects in the Phase 3 trials in HSCT recipients and in the Phase 3 trial in kidney transplant recipients.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

The safety summary for PREVYMIS® in HSCT recipients was based on data from a randomized, placebo-controlled Phase 3 clinical trial P001 in which CMV seropositive HSCT recipients received letermovir or placebo. The safety summary for PREVYMIS® in kidney transplant recipients was based on data from a randomized, active comparator-controlled Phase 3 clinical trial P002 in which kidney transplant recipients [D+/R-] received letermovir or valganciclovir.

In P001, the most commonly reported adverse reactions in subjects treated with PREVYMIS® through Week 14 post-HSCT and followed for safety through Week 24 post-HSCT were nausea, diarrhea, and vomiting. In P002, the most commonly reported adverse reactions in subjects treated with PREVYMIS®

or valganciclovir through Week 28 post-kidney transplant were leukopenia, neutropenia, and white blood cell count decreased.

## 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

### Adult CMV-seropositive Recipients [R+] of an Allogeneic HSCT

The safety of PREVYMIS® was evaluated in a Phase 3 randomized, double-blind, placebo-controlled trial (P001) through Week 14 post-HSCT and were followed for safety through Week 24 post-HSCT (see [14 CLINICAL TRIALS](#)).

The most commonly reported adverse reactions occurring in at least 1% of subjects in the PREVYMIS® group through Week 24 post-HSCT and at a frequency greater than placebo were: nausea, diarrhea, and vomiting (see [Table 2](#)).

**Table 2 - P001 Adverse Reactions Reported in ≥1% HSCT Recipients in the PREVYMIS® Group and at a Frequency Greater than Placebo Through Week 24 Post-Transplant**

	<b>PREVYMIS® n = 373 (%)</b>	<b>Placebo n = 192 (%)</b>
<b>Gastrointestinal</b>		
Nausea	27 (7.2)	7 (3.6)
Diarrhea	9 (2.4)	2 (1.0)
Vomiting	7 (1.9)	1 (1.0)

Serious adverse reactions through week 24 post-HSCT were reported in 6 (1.1%) subjects with 3 (0.8%) in the PREVYMIS® group and 3 (1.6%) in the placebo group. The reported serious adverse reactions, which had a temporal association but no other plausible causal relationship to study treatment, were pancytopenia, thrombocytopenia, and delayed engraftment in the letermovir group and Bowen’s disease, mental status changes, and acute kidney injury in the placebo group.

### **Cardiac Adverse Events:**

Cardiac adverse events were more common in subjects receiving PREVYMIS® (13%) compared to subjects receiving placebo (6%). The most common cardiac adverse events were tachycardia (reported in 4% of PREVYMIS® subjects and in 2% of placebo subjects) and atrial fibrillation (reported in 3.5% of PREVYMIS® subjects and in 1% of placebo subjects). These adverse events were mostly considered mild or moderate in severity.

Hypersensitivity was reported with PREVYMIS® in one subject.

Overall, similar proportions of subjects in each group discontinued study medication due to an adverse reaction (4.8% PREVYMIS® vs. 3.6% placebo). The most frequently reported adverse reactions that led to discontinuation of PREVYMIS® were nausea (1.6%), vomiting (0.8%), and abdominal pain (0.5%).

### Adult Kidney Transplant Recipients [D+/R-]

The safety of PREVYMIS® was evaluated in a Phase 3 randomized, double-blind, active comparator-controlled trial (P002) in which 589 subjects were treated with PREVYMIS® (N=292) or valganciclovir (N=297) through Week 28 post-transplant.

The most commonly reported adverse reactions occurring in at least 2% of subjects in the PREVYMIS® group or valganciclovir group are shown in [Table 3](#).

**Table 3- P002 Adverse Reactions Reported in ≥2% Kidney Transplant Recipients in the PREVYMIS® Group or Valganciclovir Group Through Week 28 Post-Transplant**

Adverse Reaction	PREVYMIS® (n=292) (%)	Valganciclovir (n=297) (%)
Leukopenia	20 (6.8)	68 (22.9)
Neutropenia	6 (2.1)	24 (8.1)
White blood cell count decreased	3 (1.0)	12 (4.0)

Study medication was discontinued due to an adverse reaction in 2.7% of subjects in the PREVYMIS® group and 8.8% of subjects in the valganciclovir group. The most frequently reported adverse reactions that led to study medication discontinuation were neutropenia (PREVYMIS®, 1.4%; valganciclovir, 1.3%) and leukopenia (PREVYMIS®, 1.0%; valganciclovir, 5.4%).

The proportion of subjects with leukopenia or neutropenia (adverse events of leukopenia or neutropenia, total white blood cell count <3500 cells/μL, or absolute neutrophil count <1000 cells/μL) through Week 28 post-transplant was lower in the PREVYMIS® group compared with the valganciclovir group (PREVYMIS®, 26%; valganciclovir, 64%).

#### 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

##### Clinical Trial Findings

##### Adult CMV-seropositive Recipients [R+] of an Allogeneic HSCT

Overall, the percentage of subjects with potentially clinically significant changes in laboratory values (e.g., hematology, chemistry, renal, and hepatic function) was similar in the PREVYMIS® and placebo groups. There were no differences in the incidence of or time to engraftment (defined as absolute neutrophil count ≥ 500/mm<sup>3</sup> on 3 consecutive days after transplantation) between the PREVYMIS® and placebo groups.

Biomarkers of testicular toxicity were evaluated in male subjects in P001 (see [16 NON-CLINICAL TOXICOLOGY](#)). The changes from baseline in male sex hormones (serum inhibin B, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone) were similar in the PREVYMIS® and placebo groups.

##### Adult Kidney Transplant Recipients [D+/R-]

Selected laboratory abnormalities reported through Week 28 post-transplant are presented in the table below.

**Table 4 - P002 Selected Laboratory Abnormalities**

	<b>PREVYMIS® n=292</b>	<b>Valganciclovir n=297</b>
Absolute neutrophil count (cells/μL)		
< 500	2.1%	6.7%
500 – < 750	1.4%	2.4%
750 – < 1000	1.4%	6.7%
Hemoglobin (g/dL)		
< 6.5	0.7%	0.0%
6.5 – < 8.0	3.8%	4.0%
8.0 – < 9.5	29.5%	32.0%
Platelets (cells/μL)		
< 25000	0.0%	0.0%
25000 – < 50000	0.3%	0.0%
50000 – < 100000	0.7%	2.7%
Leukocytes (cells/μL)		
< 1000	1.0%	2.0%
1000 – < 2000	4.5%	16.2%
2000 – < 3500	16.4%	36.4%
Serum creatinine (mg/dL)		
> 2.5	21.6%	21.2%
> 1.5 – 2.5	50.7%	51.5%

### 8.5 Post-Market Adverse Reactions

Not Applicable.

## 9 DRUG INTERACTIONS

### 9.1 Serious Drug Interactions

<b>Serious Drug Interactions</b>
<ul style="list-style-type: none"> <li> <p><b>• Pimozide</b> Pimozide is contraindicated with PREVYMIS®. Concomitant administration of PREVYMIS® may result in increased concentrations of pimozide due to inhibition of cytochrome P450 3A (CYP3A) by letermovir, leading to QT prolongation and torsades de pointes (see <a href="#">2 CONTRAINDICATIONS</a>, <a href="#">7 WARNINGS AND PRECAUTIONS</a> and <a href="#">9.2 Drug Interactions Overview</a>).</p> </li> <li> <p><b>• Ergot Alkaloids</b> Ergot Alkaloids are contraindicated with PREVYMIS®. Concomitant administration of PREVYMIS® may result in increased concentrations of ergot alkaloids (ergotamine and dihydroergotamine) due to inhibition of CYP3A by letermovir, which may lead to ergotism (see <a href="#">2 CONTRAINDICATIONS</a>, <a href="#">7 WARNINGS AND PRECAUTIONS</a> and <a href="#">9.2 Drug Interactions Overview</a>).</p> </li> <li> <p><b>• Cyclosporine with lovastatin, rosuvastatin or simvastatin</b> When PREVYMIS® is co-administered with cyclosporine, use of lovastatin, rosuvastatin or</p> </li> </ul>

simvastatin is contraindicated. Concomitant administration of PREVMIS® in combination with cyclosporine may result in significantly increased lovastatin, rosuvastatin or simvastatin concentrations, which may lead to myopathy or rhabdomyolysis (see [2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS](#) and [9.2 Drug Interactions Overview](#)).

- **Cyclosporine with bosentan**

Concomitant administration of PREVMIS® in combination with cyclosporine and bosentan may result in significantly increased concentrations of bosentan (see [2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS](#) and [9.2 Drug Interactions Overview](#)).

## 9.2 Drug Interactions Overview

### Effect of Other Drugs on PREVMIS®

Letermovir is a substrate of organic anion-transporting polypeptide 1B1/3 (OATP1B1/3) and P-glycoprotein (P-gp) transporters and UDP-glucuronosyltransferase 1A1/3 (UGT1A1/3) enzymes. Co-administration of PREVMIS® with drugs that are inhibitors of OATP1B1/3 transporters may result in increases in letermovir plasma concentrations. If PREVMIS® is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of PREVMIS® is 240 mg once daily (see [4.2 Recommended Dose and Dosage Adjustment, 10.3 Pharmacokinetics](#), and [Table 5](#)).

Co-administration of PREVMIS® with strong and moderate inducers of transporters (e.g., P-gp) and/or enzymes (e.g., UGTs) is not recommended due to the potential for a decrease in letermovir plasma concentrations (see [7 WARNINGS AND PRECAUTIONS](#)).

Rifampin co-administration resulted in an initial increase in letermovir plasma concentrations (due to OATP1B1/3 inhibition) that is not clinically significant, followed by clinically relevant decreases in letermovir plasma concentrations with continued rifampin co-administration. This may result in loss of prophylactic efficacy and necessitate initiation of anti-CMV therapy for CMV reactivation and/or disease (see [7 WARNINGS AND PRECAUTIONS](#)).

### Effect of PREVMIS® on Other Drugs

Letermovir is a moderate inhibitor of CYP3A, based on clinical studies using midazolam as probe. Co-administration of PREVMIS® with drugs that are CYP3A substrates may result in clinically relevant increases in the plasma concentrations of co-administered CYP3A substrates. PREVMIS® is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. PREVMIS® should be used with caution with other CYP3A substrates and adverse reactions to these drugs monitored as appropriate (see [2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS](#), and [Table 5](#)).

Letermovir is an inhibitor of OATP1B1/3 transporters BCRP, BSEP, MRP2, and UGT1A1. Co-administration of PREVMIS® with drugs that are substrates of OATP1B1/3 transporters may result in a clinically relevant increase in plasma concentrations of co-administered OATP1B1/3 substrates (see [Table 5](#)).

The magnitude of CYP3A- and OATP1B1/3-mediated drug interactions on co-administered drugs may be different when PREVMIS® is co-administered with cyclosporine. See the product monograph for cyclosporine for information on drug interactions with cyclosporine.

## 9.4 Drug-Drug Interactions



### Established and Other Potentially Significant Drug Interactions

If dose adjustments of concomitant medications are made due to treatment with PREVYMIS®, doses should be readjusted after treatment with PREVYMIS® is completed.

Table 5 provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with PREVYMIS® or are predicted drug interactions that may occur with PREVYMIS® (see [7 WARNINGS AND PRECAUTIONS](#) and [10.3 Pharmacokinetics](#)).

**Table 5 - Potentially Significant Drug Interactions: Alteration in Dose May Be Recommended Based on Results from Drug Interaction Studies or Predicted Interactions<sup>b</sup> (Information in the Table Applies to Co-administration of PREVYMIS® and the Concomitant Drug without Cyclosporine, Unless Otherwise Indicated)**

[Proper/Common name]	Source of Evidence	Effect <sup>†</sup>	Clinical comment
<b>Anti-arrhythmic Agents</b>			
amiodarone	T	↑ amiodarone	Co-administration of PREVYMIS® with amiodarone increases plasma concentrations of amiodarone. Close clinical monitoring for adverse events related to amiodarone is recommended during co-administration. Frequently monitor amiodarone concentrations when amiodarone is co-administered with PREVYMIS®. When PREVYMIS® is co-administered with cyclosporine, use of amiodarone is not recommended.
<b>Anticoagulants</b>			
warfarin	T	↓ concentrations of warfarin	Co-administration of PREVYMIS® with warfarin may decrease the plasma concentrations of warfarin. Frequent monitoring of INR should be performed while warfarin is co-administered with PREVYMIS® <sup>§</sup> .
<b>Anticonvulsants</b>			
carbamazepine	T	↓ letermovir	Co-administration of PREVYMIS® with carbamazepine may decrease plasma concentrations of letermovir. Co-administration of PREVYMIS® and carbamazepine is not recommended.
phenobarbital	T	↓ letermovir	Co-administration of PREVYMIS® with phenobarbital may decrease plasma concentrations of letermovir. Co-administration of PREVYMIS® and phenobarbital is not recommended.

[Proper/Common name]	Source of Evidence	Effect <sup>†</sup>	Clinical comment
phenytoin	T	↓ letermovir ↓ phenytoin	Co-administration of PREVYMIS® with phenytoin may decrease plasma concentrations of letermovir. PREVYMIS® may decrease the plasma concentrations of phenytoin. Frequent monitoring of phenytoin concentrations should be performed when phenytoin is co-administered with PREVYMIS®. Co-administration of PREVYMIS® and phenytoin is not recommended.
<b>Antidiabetic Agents</b>			
Examples: glyburide, repaglinide, rosiglitazone	T <sup>¶</sup>	↑ glyburide ↑ repaglinide ↑ rosiglitazone	Co-administration of PREVYMIS® with glyburide, repaglinide, or rosiglitazone may increase the plasma concentrations of these drugs. Frequent monitoring of glucose concentrations is recommended during co-administration of glyburide, repaglinide, and rosiglitazone <sup>§</sup> . When PREVYMIS® is co-administered with cyclosporine, use of repaglinide is not recommended.
<b>Antifungals</b>			
voriconazole	CT	↓ voriconazole	Co-administration of PREVYMIS® with voriconazole decreases plasma concentrations of voriconazole. If concomitant administration is necessary, close monitoring for reduced effectiveness of voriconazole is recommended <sup>§</sup> .
<b>Antimycobacterials</b>			
rifabutin	T	↓ letermovir	Co-administration of PREVYMIS® with rifabutin may decrease plasma concentrations of letermovir. Co-administration of PREVYMIS® and rifabutin is not recommended.

[Proper/Common name]	Source of Evidence	Effect <sup>†</sup>	Clinical comment
rifampin	CT	↓ letermovir	Co-administration of PREVMIS® with rifampin decreases plasma concentrations of letermovir, which may result in loss of prophylactic efficacy and necessitate initiation of anti-CMV therapy for CMV reactivation and/or disease. Co-administration of PREVMIS® and rifampin is not recommended.
<b>Endothelin Antagonists</b>			
bosentan	T	↓ letermovir	When PREVMIS® is co-administered with cyclosporine, the use of bosentan is contraindicated (see <a href="#">2 CONTRAINDICATIONS</a> ).  Co-administration of PREVMIS® with bosentan may decrease plasma concentrations of letermovir. Co-administration of bosentan with PREVMIS® is not recommended.
<b>Herbal Products</b>			
St. John's wort ( <i>Hypericum perforatum</i> )	T	↓ letermovir	Co-administration of PREVMIS® with St. John's wort may decrease plasma concentrations of letermovir. Co-administration of PREVMIS® and St. John's wort is not recommended.
<b>HIV Medications</b>			
efavirenz	T	↓ letermovir	Co-administration of PREVMIS® with efavirenz may decrease plasma concentrations of letermovir. Co-administration of PREVMIS® and efavirenz is not recommended.
etravirine	T	↓ letermovir	Co-administration of PREVMIS® with etravirine may decrease plasma concentrations of letermovir. Co-administration of PREVMIS® and etravirine is not recommended.
nevirapine	T	↓ letermovir	Co-administration of PREVMIS® with nevirapine may decrease plasma concentrations of letermovir. Co-administration of PREVMIS® and nevirapine is not recommended.
<b>HMG-CoA Reductase Inhibitors</b>			

[Proper/Common name]	Source of Evidence	Effect <sup>†</sup>	Clinical comment
atorvastatin	CT	↑ atorvastatin	Co-administration of PREVYMIS <sup>®</sup> with atorvastatin increases plasma concentrations of atorvastatin. The dose of atorvastatin should not exceed 20 mg daily when co-administered with PREVYMIS <sup>®</sup> <sup>§</sup> . Closely monitor patients for adverse reactions such as myopathy. When PREVYMIS <sup>®</sup> is co-administered with cyclosporine, use of atorvastatin is not recommended.
Simvastatin, lovastatin, rosuvastatin	T	↑ simvastatin lovastatin rosuvastatin	When PREVYMIS <sup>®</sup> is co-administered with cyclosporine, the use of lovastatin or rosuvastatin or simvastatin is contraindicated (see <a href="#">2 CONTRAINDICATIONS</a> ). Concomitant use with PREVYMIS <sup>®</sup> is not recommended.
fluvastatin, pravastatin	T	↑ fluvastatin, pravastatin	When PREVYMIS <sup>®</sup> is co-administered with these statins, a statin dosage reduction may be necessary <sup>§</sup> . Closely monitor patients for adverse reactions such as myopathy. When PREVYMIS <sup>®</sup> is co-administered with cyclosporine, refer to the statin product monograph for specific statin dosing recommendations <sup>§</sup> .
<b>Immunosuppressants</b>			

[Proper/Common name]	Source of Evidence	Effect <sup>†</sup>	Clinical comment
cyclosporine	CT	↑ cyclosporine ↑ letermovir	<p>Co-administration of PREVYMIS® with cyclosporine increases concentrations of both letermovir and cyclosporine.</p> <p>When PREVYMIS® is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor), the dosage of PREVYMIS® should be decreased to 240 mg once daily (see <a href="#">4.2 Recommended Dose and Dosage adjustment</a> and <a href="#">10.3 Pharmacokinetics</a>).</p> <p>Frequent monitoring of cyclosporine whole blood concentrations should be performed during and at discontinuation of PREVYMIS® and the dose of cyclosporine adjusted accordingly<sup>§</sup>.</p>
sirolimus	CT	↑ sirolimus	<p>Co-administration of PREVYMIS® with sirolimus increases concentrations of sirolimus. Frequent monitoring of sirolimus whole blood concentrations should be performed during and at discontinuation of PREVYMIS® and the dose of sirolimus adjusted accordingly<sup>§</sup>.</p> <p>When PREVYMIS® is co-administered with cyclosporine, refer to the sirolimus product monograph for specific sirolimus dosing recommendations<sup>§</sup>.</p>
tacrolimus	CT	↑ tacrolimus	<p>Co-administration of PREVYMIS® with tacrolimus increases tacrolimus plasma concentrations. Frequent monitoring of tacrolimus whole blood concentrations should be performed during and at discontinuation of PREVYMIS® and the dose of tacrolimus adjusted accordingly<sup>§</sup>.</p>
<b>Proton Pump Inhibitors</b>			

[Proper/Common name]	Source of Evidence	Effect <sup>†</sup>	Clinical comment
omeprazole pantoprazole	T	↓omeprazole ↓pantoprazole	Co-administration of PREVYMIS® with these proton pump inhibitors (PPI) may decrease plasma concentrations of the PPIs. Clinical monitoring and dose adjustment may be needed when co-administered with PREVYMIS® <sup>5</sup> .
<b>Wakefulness-Promoting Agents</b>			
modafinil	T	↓ letermovir	Co-administration of PREVYMIS® with modafinil may decrease plasma concentrations of letermovir.  Co-administration of PREVYMIS® and modafinil is not recommended.
<b>CYP3A Substrates</b>			

[Proper/Common name]	Source of Evidence	Effect <sup>†</sup>	Clinical comment
Examples: alfentanil, fentanyl, midazolam, quinidine <sup>1</sup>	T, CT	↑ concentrations of CYP3A substrate	<p>PREVYMIS® may increase the plasma concentrations of CYP3A substrates.</p> <p>Frequent monitoring for adverse reactions related to CYP3A substrates is recommended during co-administration. Dose adjustment of CYP3A substrates may be needed<sup>§</sup> (see <a href="#">7 WARNINGS AND PRECAUTIONS</a>).</p> <p>When PREVYMIS® is co-administered with a CYP3A substrate, refer to the product monograph for dosing of the CYP3A substrate with a moderate CYP3A inhibitor<sup>§</sup>.</p> <p>When PREVYMIS® is co-administered with alfentanil, fentanyl, and midazolam, closely monitor patients for adverse reactions such as respiratory depression and prolonged sedation.</p> <p>When PREVYMIS® is co-administered with quinidine, closely monitor patients for adverse reactions such as ventricular arrhythmia and hypotension.</p> <p>When PREVYMIS® is co-administered with cyclosporine, the combined effect on CYP3A substrates may be similar to a strong CYP3A inhibitor. Refer to the CYP3A substrate product monograph for dosing of the CYP3A substrate with a strong CYP3A inhibitor<sup>§</sup>.</p>
<p><sup>β</sup> This table is not all inclusive.</p> <p><sup>†</sup> ↓ =decrease, ↑=increase</p> <p><sup>§</sup> Refer to the respective product monograph.</p> <p><sup>¶</sup> Effect on concentration for repaglinide and rosiglitazone is based on physiologically based pharmacokinetic modeling.</p>			

Legend: CT = Clinical Trial; T = Theoretical

**Drugs without Clinically Significant Interactions with PREVYMIS®**

There was no clinically relevant interaction when PREVYMIS® was co-administered with itraconazole, a P-gp/BCRP inhibitor.

There were no clinically relevant changes in plasma concentrations of digoxin, a P-gp substrate, and acyclovir, an OAT3 substrate, following co-administration with PREVYMIS® in clinical studies (see below).

The interaction between letermovir and the following drugs was evaluated in clinical studies: mycophenolate mofetil, fluconazole, posaconazole, and oral combinations of ethinyl estradiol/levonorgestrel. No dose adjustments are needed when PREVYMIS® is used with these drugs.

#### Drug Interaction Studies

Drug interaction studies were performed in healthy subjects with PREVYMIS® and drugs likely to be co-administered or drugs commonly used as probes for pharmacokinetic interactions (see [Table 6](#) and [Table 7](#)).

*In vitro* results indicate that letermovir is a substrate of OATP1B1/3, P-gp, UGT1A1, and UGT1A3. Inhibitors of OATP1B1/3 transporters may result in increases in letermovir plasma concentrations. If PREVYMIS® is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of PREVYMIS® is 240 mg once daily (see [4.2 Recommended Dose and Dosage Adjustment](#)). Changes in letermovir plasma concentrations due to inhibition of P-gp/BCRP by itraconazole were not clinically relevant. Inhibition of UGTs is not anticipated to have a clinically relevant effect on letermovir plasma concentrations. Induction of drug enzymes (e.g., UGTs) and/or transporters (e.g., P-gp) by rifampin may result in clinically relevant decreases in letermovir plasma concentrations; therefore, co-administration of strong and moderate inducers with letermovir is not recommended (see [Effect of Other Drugs on PREVYMIS®](#), [Table 5](#), and [Table 6](#)). Although CYP3A, CYP2D6 and CYP2J2 were identified as enzymes capable of mediating the metabolism of letermovir *in vitro*, oxidative metabolism is considered to be a minor elimination pathway based on *in vivo* human data.

Letermovir is a time-dependent inhibitor and inducer of CYP3A *in vitro*. Co-administration of PREVYMIS® with midazolam resulted in increased exposure of midazolam, indicating that the net effect of letermovir on CYP3A is moderate inhibition (see [Table 5](#)). Based on these results, co-administration of PREVYMIS® with CYP3A substrates may increase the plasma concentrations of the CYP3A substrates (see [2 CONTRAINDICATIONS](#), [7 WARNINGS AND PRECAUTIONS](#), [9.4 Drug-Drug Interactions](#), and [Table 5](#)). Letermovir is a reversible inhibitor of CYP2C8 *in vitro*. Physiologically based pharmacokinetic modeling predicts an increase in plasma concentrations of CYP2C8 substrates when co-administered with PREVYMIS® (see [Table 5](#) in [9.4 Drug-Drug Interactions](#)). Co-administration of PREVYMIS® reduced the exposure of voriconazole, most likely due to the induction of voriconazole elimination pathways, CYP2C9 and CYP2C19. Co-administration of PREVYMIS® with CYP2C9 and CYP2C19 substrates may decrease the plasma concentrations of the CYP2C9 and CYP2C19 substrates (see [Table 5](#) in [9.4 Drug-Drug Interactions](#)). Letermovir is an inducer of CYP2B6 *in vitro*; the clinical relevance is unknown.

Letermovir inhibited efflux transporters P-gp, breast cancer resistance protein (BCRP), bile salt export pump (BSEP), multidrug resistance-associated protein 2 (MRP2), OAT3, and hepatic uptake transporter OATP1B1/3 *in vitro*. Co-administration of PREVYMIS® with substrates of OATP1B1/3 transporters (e.g., atorvastatin, a known substrate of CYP3A, OATP1B1/3, and potentially BCRP) may result in a clinically relevant increase in plasma concentrations of OATP1B1/3 substrates (see [Table 5](#) in [9.4 Drug-Drug Interactions](#)). There were no clinically relevant changes in plasma concentrations of digoxin, a P-gp substrate, or acyclovir, an OAT3 substrate, following co-administration with PREVYMIS® in clinical studies (see [Table 7](#)). The effect of letermovir on BCRP, BSEP, and MRP2 substrates was not evaluated in clinical studies; the clinical relevance is unknown.



**Table 6 - Drug Interactions: Changes in Pharmacokinetics of Letemovir in the Presence of Co-Administered Drug**

Co-administered Drug	Regimen of Co-administered Drug	Letemovir Regimen	N	Geometric Mean Ratio [90% CI] of Letemovir PK with/without Co-administered Drug (No Effect=1.00)	
				AUC	Cmax
<b>Antifungals</b>					
fluconazole	400 mg single dose PO	480 mg single dose PO	14	1.11 (1.01, 1.23)	1.06 (0.93, 1.21)
itraconazole	200 mg once daily PO	480 mg once daily PO	14	1.33 (1.17, 1.51)	1.21 (1.05, 1.39)
<b>Antimycobacterials</b>					
rifampin	600 mg single dose PO	480 mg single dose PO	16	2.03 (1.84, 2.26)	1.59 (1.46, 1.74)
	600 mg single dose IV	480 mg single dose PO	16	1.58 (1.38, 1.81)	1.37 (1.16, 1.61)
	600 mg once daily PO**	480 mg once daily PO	14	0.81 (0.67, 0.98)	1.01 (0.79, 1.28)
	600 mg once daily PO (24 hours after rifampin) <sup>†</sup>	480 mg once daily PO	14	0.15 (0.13, 0.17)	0.27 (0.22, 0.31)
<b>Immunosuppressants</b>					
cyclosporine	200 mg single dose PO	240 mg once daily PO	12	2.11 (1.97, 2.26)	1.48 (1.33, 1.65)
mycophenolate mofetil	1 g single dose PO	480 mg once daily PO	14	1.18 (1.04, 1.32)	1.11 (0.92, 1.34)
tacrolimus	5 mg single dose PO	80 mg twice daily PO	14	1.02 (0.97, 1.07)	0.92 (0.84, 1.00)
Abbreviations: PO= oral ** C <sub>24</sub> GMR [90%] is 0.14 (0.11, 0.19) <sup>†</sup> These data are the effect of rifampin on letemovir 24 hours after final rifampin dose. C <sub>24</sub> GMR [90%] is 0.09 (0.06, 0.12).					

**Table 7 - Drug Interactions: Changes in Pharmacokinetics for Co-Administered Drug in the Presence of Letemovir or Co-Administered Letemovir**

Co-administered Drug	Regimen of Co-administered Drug	Letemovir Regimen	N	Geometric Mean Ratio [90% CI] of Co-administered Drug PK with/without Letemovir (No Effect=1.00)	
				AUC	Cmax
<b>CYP3A Substrates</b>					
midazolam	1 mg single dose IV	240 mg once daily PO	16	1.47 (1.37, 1.58)	1.05 (0.94, 1.17)
	2 mg single dose PO	240 mg once daily PO	16	2.25 (2.04, 2.48)	1.72 (1.55, 1.92)
<b>P-gp Substrates</b>					
digoxin	0.5 mg single dose PO	240 mg twice daily PO	22	0.88 (0.80, 0.96)	0.75 (0.63, 0.89)
<b>Immunosuppressants</b>					
cyclosporine	50 mg single dose PO	240 mg once daily PO	14	1.66 (1.51, 1.82)	1.08 (0.97, 1.19)
mycophenolate mofetil	1 g single dose PO	480 mg once daily PO	14	1.08 (0.97, 1.20)	0.96 (0.82, 1.12)
tacrolimus	5 mg single dose PO	480 mg once daily PO	13	2.42 (2.04, 2.88)	1.57 (1.32, 1.86)
sirolimus	2 mg single dose PO	480 mg once daily PO	13	3.40 (3.01, 3.85)	2.76 (2.48, 3.06)
<b>Antifungals and Antivirals</b>					
acyclovir	400 mg single dose PO	480 mg once daily PO	13	1.02 (0.87, 1.2)	0.82 (0.71, 0.93)
fluconazole	400 mg single dose PO	480 mg single dose PO	14	1.03 (0.99, 1.08)	0.95 (0.92, 0.99)
itraconazole	200 mg once daily PO	480 mg once daily PO	14	0.76 (0.71, 0.81)	0.84 (0.76, 0.92)
posaconazole	300 mg single dose PO	480 mg once daily PO	13	0.98 (0.82, 1.17)	1.11 (0.95, 1.29)
voriconazole	200 mg twice daily PO	480 mg once daily PO	12	0.56 (0.51, 0.62)	0.61 (0.53, 0.71)
<b>HMG-CoA Reductase Inhibitors</b>					
atorvastatin	20 mg single dose PO	480 mg once daily PO	14	3.29 (2.84, 3.82)	2.17 (1.76, 2.67)
<b>Oral Contraceptives</b>					

Co-administered Drug	Regimen of Co-administered Drug	Letermovir Regimen	N	Geometric Mean Ratio [90% CI] of Co-administered Drug PK with/without Letermovir (No Effect=1.00)	
				AUC	C <sub>max</sub>
ethinyl estradiol (EE) /levonorgestrel (LNG)	0.03 mg EE single dose PO	480 mg once daily PO	22	1.42 (1.32, 1.52)	0.89 (0.83, 0.96)
	0.15 mg LNG single dose PO		22	1.36 (1.30, 1.43)	0.95 (0.86, 1.04)

Abbreviations: PO=oral

### 9.5 Drug-Food Interactions

Food increases peak levels ( $C_{max}$ ) but not exposure ( $AUC_T$ ) of PREVMIS<sup>®</sup> following administration with a high fat, high calorie meal (see [4.1 Dosing Considerations](#) and [10.3 Pharmacokinetics, Absorption, Effect of Food](#)).

### 9.6 Drug-Herb Interactions

Co-administration of PREVMIS<sup>®</sup> with St. John's wort (*Hypericum perforatum*) may decrease plasma concentrations of letermovir.

Co-administration of PREVMIS<sup>®</sup> and St. John's wort is not recommended (see [Table 5](#) in [9.4 Drug-Drug Interactions](#)).

### 9.7 Drug-Laboratory Test Interactions

Interactions with clinical laboratory tests have not been established.

## 10 CLINICAL PHARMACOLOGY

### 10.1 Mechanism of Action

PREVMIS<sup>®</sup> is an antiviral drug against CMV (see [15 MICROBIOLOGY](#)).

### 10.2 Pharmacodynamics

#### Cardiac Electrophysiology

The effect of letermovir on doses up to 960 mg given IV on the QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg oral) 4-period crossover thorough QT trial in 38 healthy subjects. Letermovir did not prolong QTc to any clinically relevant extent following the 960 mg IV dose with plasma concentrations approximately 2-fold higher than the 480 mg IV dose.

### 10.3 Pharmacokinetics

The pharmacokinetics of letermovir have been characterized following oral and IV administration in healthy subjects and HSCT recipients and following oral administration in kidney transplant recipients.

#### Healthy Subjects

Letermovir exposure increased in a greater than dose-proportional manner with both oral or IV administration following single and multiple doses of 240 mg and 480 mg. Letermovir was absorbed rapidly with a median time to maximum plasma concentration ( $T_{max}$ ) of 1.5 to 3.0 hours and declined in a biphasic manner. The geometric mean steady-state AUC and  $C_{max}$  values were 71,500 ng•hr/mL and 13,000 ng/mL, respectively, with 480 mg once daily oral PREVYMIS®. The post-absorption plasma concentration-time profile of letermovir following oral administration was similar to the profile observed with IV dosing. Letermovir clearance (CL) reached steady-state in 9 to 10 days with an accumulation ratio of 1.22 for AUC and 1.03 for  $C_{max}$ .

### HSCT Recipients

Letermovir AUC was estimated using population pharmacokinetic analyses using Phase 3 data (see Table 8). Differences in exposure across treatment regimens are not clinically relevant; efficacy was consistent across the range of exposures observed in P001.

**Table 8 - Letermovir AUC (ng•hr/mL) Values in HSCT Recipients**

Treatment Regimen	Median (90% Prediction Interval) <sup>β</sup>
480 mg Oral, no cyclosporine	34,400 (16,900, 73,700)
480 mg IV, no cyclosporine	100,000 (65,300, 148,000)
240 mg Oral, with cyclosporine	60,800 (28,700, 122,000)
240 mg IV, with cyclosporine	70,300 (46,200, 106,000)
<sup>β</sup> Medians and 90% prediction intervals are based on simulations using the Phase 3 population PK model with inter-individual variability.	

### Kidney Transplant Recipients

Letermovir AUC was estimated using population pharmacokinetic analysis using Phase 3 data (see Table 9). Efficacy was consistent across the range of exposures observed in P002.

**Table 9 - Letermovir AUC (ng•hr/mL) Values in Kidney Transplant Recipients**

Treatment Regimen	Median (90% Prediction Interval) <sup>β</sup>
480 mg Oral, no cyclosporine	62,200 (28,900, 145,000)
240 mg Oral, with cyclosporine	57,700 (26,900, 135,000)
<sup>β</sup> Medians and 90% prediction intervals are based on simulations using the Phase 3 population PK model with inter-individual variability.	

### Absorption

In healthy subjects, absolute bioavailability of letermovir was estimated to be approximately 94% over

the dose range 240 mg to 480 mg based on population pharmacokinetic analyses. In HSCT recipients, bioavailability of letermovir was estimated to be approximately 35% with 480 mg once daily oral PREVYMIS® administered without cyclosporine. The inter-individual variability for bioavailability was estimated to be approximately 37%. In kidney transplant recipients, bioavailability of letermovir was estimated to be approximately 60% with 480 mg once daily oral PREVYMIS® administered without cyclosporine.

#### Effect of Cyclosporine

In HSCT recipients, co-administration of cyclosporine increased plasma concentrations of letermovir. Bioavailability of letermovir was estimated to be approximately 85% with 240 mg once daily oral PREVYMIS® co-administered with cyclosporine. If PREVYMIS® is co-administered with cyclosporine, the recommended dose of PREVYMIS® is 240 mg once daily (see [4.2 Recommended Dose and Dosage Adjustment](#)).

#### Effect of Food

Relative to administration under fasting conditions, oral administration of a single 480 mg dose of PREVYMIS® 480 mg tablets with a standard high fat, high calorie meal resulted in no significant effect on overall exposure ( $AUC_T$ ) of letermovir and an increase in peak levels ( $C_{max}$ ) of approximately 30%. The increase in  $C_{max}$  is not clinically relevant (see [4.1 Dosing Considerations](#) and [9.5 Drug-Food Interactions](#)).

#### **Distribution:**

Based on population pharmacokinetic analyses, the mean steady-state volume of distribution is estimated to be 45.5 L following IV administration in HSCT recipients.

Letermovir is extensively bound (98.7%) to human plasma proteins *in vitro*. Blood to plasma partitioning of letermovir is 0.56 and independent of the concentration range (0.1 to 10 mg/L) evaluated *in vitro*.

In preclinical distribution studies, letermovir is distributed to organs and tissues with the highest concentrations observed in the gastrointestinal tract, bile duct and liver and low concentrations in the brain.

In pregnant rats, letermovir was able to cross the placenta (see [7.1 Special Populations, Pregnant Women](#)).

#### **Metabolism:**

The majority of drug-related component in plasma is unchanged parent (96.6%). No major metabolites are detected in plasma. Letermovir is partly eliminated by glucuronidation mediated by UGT1A1/1A3.

#### **Elimination**

The mean apparent terminal half-life for letermovir is approximately 12 hours with 480 mg IV PREVYMIS® in healthy subjects.

#### Excretion

Based on population pharmacokinetic analyses, letermovir steady-state CL is estimated to be 4.84 L/hr following IV administration in HSCT recipients. The inter-individual variability for CL is estimated to be 24.6%.

After oral administration of radio-labeled letermovir, 93.3% of radioactivity was recovered in feces. The majority of drug was excreted as unchanged parent with a minor amount (6% of dose) as an acyl-glucuronide metabolite in feces. Urinary excretion of letermovir was negligible (<2% of dose).

### Special Populations and Conditions

- **Pediatrics:** The pharmacokinetics of letermovir in pediatric patients less than 18 years of age have not been evaluated.
- **Geriatrics:** Based on population pharmacokinetic analyses, there is no effect of age on letermovir pharmacokinetics. No dose adjustment is required based on age.
- **Sex:** Based on population pharmacokinetic analyses, there is no difference in letermovir pharmacokinetics in females compared to males.
- **Genetic Polymorphism:** The impact of genetic variants in the OATP1B1 gene SLCO1B1 (rs4149056, rs2306283, rs4149032) and UGT1A1 (rs4148323 and the promoter TA repeat variants) on the pharmacokinetics of letermovir was evaluated in 299 study participants. There was no clinically relevant impact of these variants on letermovir exposures.
- **Ethnic Origin:** Based on Phase 1 population pharmacokinetic analyses, letermovir AUC is estimated to be 33.2% higher in Asians compared to Whites. This change is not clinically relevant.
- **Hepatic Insufficiency:** Letermovir AUC was approximately 1.6- and 3.8-fold higher in subjects with moderate (Child-Pugh Class B [CP-B], score of 7-9) and severe (Child-Pugh Class C [CP-C], score of 10-15) hepatic impairment, respectively, compared to healthy subjects. The changes in letermovir exposure in subjects with moderate hepatic impairment are not clinically relevant.

Clinically relevant increases in letermovir exposure are anticipated in patients with severe hepatic impairment.

- **Renal Insufficiency:**
  - *Clinical Study in a Renally Impaired Population*  
Letermovir AUC was approximately 1.9- and 1.4-fold higher in subjects with moderate (eGFR greater than or equal to 30 to 59 mL/min/1.73m<sup>2</sup>) and severe (eGFR less than 30 mL/min/1.73m<sup>2</sup>) renal impairment, respectively, compared to healthy subjects. The changes in letermovir exposure due to renal impairment are not clinically relevant.
  - *Post-kidney Transplant*  
Based on population pharmacokinetic analysis, letermovir AUC was approximately 1.1-, 1.3- and 1.4-fold higher in subjects with mild (CrCl greater than or equal to 60 to less than 90 mL/min), moderate (CrCl greater than or equal to 30 to less than 60 mL/min) and severe (CrCl greater than or equal to 15 to less than 30 mL/min) renal impairment, respectively, compared to subjects with CrCl greater than or equal to 90 mL/min. These changes are not

clinically relevant.

- **Combined Renal and Hepatic Insufficiency:** Clinically relevant increases in letermovir exposure are anticipated in patients with moderate hepatic impairment combined with moderate or severe renal impairment.
- **Obesity:** Based on Phase 1 population pharmacokinetic analyses, letermovir AUC is estimated to be 18.7% lower in subjects weighing 80-100 kg compared to subjects weighing 67 kg. Based on population pharmacokinetic analysis in kidney transplant recipients, letermovir AUC is estimated to be 26% lower in subjects weighing greater than 80 kg compared to subjects weighing less than or equal to 80 kg. These changes are not clinically relevant.

## 11 STORAGE, STABILITY AND DISPOSAL

Tablets and solution for injection:

Store PREVYMIS® tablets in the original package until use.

Store PREVYMIS® tablets at room temperature (15°C to 30°C).

Store PREVYMIS® for injection vials at 15°C to 25°C. Store in the original carton to protect from exposure to light.

## 12 SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.

<sup>1</sup> Not marketed in Canada.





**Table 10 - Summary of Trial Design and Patient Demographics for the Phase III Trial in HSCT Recipients (P001)**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Other Demographic Characteristics	Baseline Patient Characteristics
P001	Randomized, double-blind, placebo-controlled, multi-site	PREVYMIS®: 480 mg QD or 240 mg QD dose, if given concomitantly with CsA, through Week 14 (~100 days) post-HSCT; dose is the same for both oral tablets and IV formulation.  Placebo: matching placebo oral tablets for letermovir oral tablets; normal saline or 5% dextrose as placebo comparator for IV letermovir formulation	Total: 565 PREVYMIS®: 373 Placebo: 192	Mean: 50.8 years  Median: 54 years  Range: (18 - 78 years)	Male: 58% Female: 42% 10% were Asian; 2% were Black or African; and 7% were Hispanic or Latino	The most common primary reasons for HSCT were acute myeloid leukemia (38%), myeloblastic syndrome (15%), and lymphoma (13%). 50% of subjects received a myeloablative regimen, 52% were receiving cyclosporine, and 42% were receiving tacrolimus. Twelve percent (12%) of subjects were positive for CMV DNA at baseline.

Subjects were randomized (2:1) to receive either PREVYMIS® or placebo. Randomization was stratified by investigational site and risk level for CMV reactivation at the time of study entry. Study drug was initiated after HSCT (Day 0-28 post-HSCT) and continued through Week 14 post-HSCT. Subjects were monitored through Week 24 post-HSCT for the primary efficacy endpoint.

At baseline, 31% of subjects were in the high risk stratum as defined by one or more of the following criteria: Human Leukocyte Antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B or -DR, haploidentical donor; unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and -DRB1; use of umbilical cord blood as stem cell source; use of *ex vivo* T-cell-depleted grafts; Grade 2 or greater Graft-Versus-Host Disease (GVHD), requiring systemic corticosteroids. The remaining 69% of subjects did not meet

any of these high risk stratum criteria and were therefore included in the low risk stratum.

*Clinically Significant CMV Infection*

The primary efficacy endpoint of P001 was the incidence of clinically significant CMV infection through Week 24 post-HSCT. Clinically significant CMV infection was defined as the occurrence of either CMV end-organ disease, or initiation of anti-CMV pre-emptive therapy (PET) based on documented CMV viremia (using the Roche COBAS\* AmpliPrep/COBAS TaqMan\* assay, Lower Limit of Quantification (LLoQ) is 137 IU/mL, which is approximately 150 copies/mL) and the clinical condition of the subject. The Non-Completer=Failure (NC=F) approach was used, where subjects who discontinued from the study prior to Week 24 post-HSCT or had a missing outcome at Week 24 post-HSCT were counted as failures.

PREVYMIS® demonstrated superior efficacy over placebo in the analysis of the primary endpoint, as shown in Table 11. The estimated treatment difference of -23.5% was statistically significant (one-sided p-value <0.0001).

**Table 11- P001 Efficacy Results in HSCT Recipients (NC=F Approach, FAS Population)**

Parameter	PREVYMIS® (N=325) n (%)	Placebo (N=170) n (%)
<b>Primary Endpoint (Proportion of subjects who failed prophylaxis)</b>	<b>122 (37.5)</b>	<b>103 (60.6)</b>
<b>Reasons for Failures<sup>β</sup></b>		
Clinically significant CMV infection by Week 24 <sup>†</sup>	57 (17.5)	71 (41.8)
Initiation of PET based on documented CMV viremia	52 (16.0)	68 (40.0)
CMV end-organ disease	5 (1.5)	3 (1.8)
Discontinued from study before Week 24	56 (17.2)	27 (15.9)
Missing outcome in Week 24 visit window	9 (2.8)	5 (2.9)
<b>Stratum-adjusted treatment difference (PREVYMIS®-Placebo)<sup>‡</sup></b>		
Difference (95% CI)	-23.5 (-32.5, -14.6)	
p-value	<0.0001	

<sup>β</sup> The categories of failure are mutually exclusive and based on the hierarchy of categories in the order listed.

<sup>†</sup> Clinically significant CMV infection was defined as CMV end organ disease or initiation of PET based on documented CMV viremia and the clinical condition of the subject.

<sup>‡</sup> 95% CIs and p-value for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (high or low risk). A 1-sided p-value ≤0.0249 was used for declaring statistical significance.

Note: FAS=Full analysis set; FAS includes randomized subjects who received at least one dose of study medication, and excludes subjects with detectable CMV DNA at baseline. Approach to handling missing values: Non-Completer=Failure (NC=F) approach. With NC=F approach, failure was defined as all subjects who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through Week 24 post-HSCT visit window.

N = number of subjects in each treatment group. n (%) = Number (percent) of subjects in each sub-category.
---

At Week 14 post-HSCT, the Kaplan-Meier (K-M) event rate for clinically significant CMV infection was 6.8% in the PREVYMIS® group compared to 41.3% in the placebo group. At Week 24 post-HSCT, the K-M event rate for clinically significant CMV infection was 18.9% in the PREVYMIS® group compared to 44.3% in the placebo group (nominal two-sided stratified log-rank p-value<0.0001). Factors associated with clinically significant CMV infection between Week 14 and Week 24 post-HSCT among PREVYMIS®-treated subjects included high risk for CMV reactivation at baseline, having GVHD, and steroid use at any time after randomization.

Of the 373 subjects treated with PREVYMIS® in P001, 56 (15.0%) subjects were 65 years of age or older. Safety and efficacy were similar across older and younger subjects.

Efficacy consistently favored PREVYMIS® across subgroups including low and high risk strata for CMV reactivation, stem cell source, donor mismatch, haploidentical transplant, conditioning regimens, and concomitant immunosuppressive regimens.

#### *Mortality*

The K-M event rate for all-cause mortality in the letermovir vs. placebo groups was 12.1% vs. 17.2% at Week 24 post-HSCT, and 23.8% vs. 27.6% at Week 48 post-HSCT.

The K-M event rate for CMV-related mortality (defined as death due to any reason in patients with clinically significant CMV infection [primary endpoint]) in the letermovir vs. placebo group was 0.7% vs. 9.1% at Week 24 post-HSCT (nominal two-sided stratified log-rank p-value < 0.0001), and 3.6% vs. 16.0% at Week 48 post-HSCT (nominal two-sided stratified log rank p-value < 0.0001).

#### **Adult CMV-seronegative Recipients of a Kidney Transplant from a CMV-seropositive Donor [D+/R-]**

A phase III study to evaluate the efficacy of PREVYMIS® prophylaxis as a preventive strategy for CMV disease in adult kidney transplant recipients at high risk [D+/R-]. A summary of trial design and demographics is presented in Table 12:

**Table 12 - Summary of Trial Design and Patient Demographics for the Phase III Trial in Kidney Transplant Recipients (P002)**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Other Demographic Characteristics	Baseline Patient Characteristics
P002	Randomized, double-blind, active comparator-controlled, non-inferiority, multi-site	PREVYMIS®: 480 mg QD or 240 mg QD dose, if given concomitantly with CsA, through Week 28 (~200 days) post-kidney transplant; dose is the same for both oral tablets and IV formulation. Acyclovir 400 mg twice daily was given concomitantly.  Valganciclovir: 900 mg QD (oral) or ganciclovir 5 mg/kg QD (IV); adjusted based on renal function	Total: 589 PREVYMIS®: 292 Valganciclovir : 297	Mean: 49.6 years  Median : 51 years  Range: (18 - 82 years)	Male: 72% Female: 28% 2% were Asian; 9% were Black or African; and 17% were Hispanic or Latino  60% received a kidney from a deceased donor	The most common primary reasons for transplant were congenital cystic kidney disease (17%), hypertension (16%), and diabetes/diabetic nephropathy (14%).

Subjects were randomized (1:1) to receive either PREVYMIS® or valganciclovir. PREVYMIS® was given concomitantly with acyclovir for herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis. Subjects randomized to the valganciclovir group were given a placebo to acyclovir. Randomization was stratified by the use or nonuse of highly cytolytic, anti-lymphocyte immunotherapy during induction. Study drug was initiated between Day 0 and Day 7 post-kidney transplant and continued through Week 28 (~200 days) post-transplant. Subjects were monitored through Week 52 post-transplant.

### CMV Disease

The primary efficacy endpoint of P002 was the incidence of CMV disease (CMV end-organ disease or CMV syndrome, confirmed by an independent adjudication committee) through Week 52 post-transplant. The Observed Failure (OF) approach was used, where subjects who discontinued prematurely from the study for any reason or were missing data at the timepoint were not considered failures. The number of subjects who discontinued from the study before Week 52 was 32 (11.1%) in the PREVYMIS® group and 28 (9.4%) in the valganciclovir group. The number of subjects with a missing outcome in the Week 52 visit window was 24 (8.3%) in the PREVYMIS® group and 25 (8.4%) in the valganciclovir group.

Based on a non-inferiority margin of 10%, PREVYMIS® demonstrated non-inferiority to valganciclovir in the analysis of the primary endpoint, as shown in Table 13.

**Table 13: P002 Efficacy Results in Kidney Transplant Recipients (OF Approach, FAS Population)**

Parameter	PREVYMIS® (N=289) n (%)	Valganciclovir (N=297) n (%)
<b>CMV disease<sup>β</sup> through Week 52</b>	<b>30 (10.4)</b>	<b>35 (11.8)</b>
CMV Syndrome <sup>§</sup>	24 (8.3)	34 (11.4)
CMV End-Organ Disease	6 (2.1)	1 (0.3)
<b>Stratum-adjusted treatment difference (PREVYMIS®-Valganciclovir)<sup>†</sup></b>	<b>-1.4 (-6.5, 3.8)<sup>‡</sup></b>	
Difference (95% CI)		
<p><sup>β</sup> CMV disease cases confirmed by an independent adjudication committee.</p> <p><sup>§</sup> CMV syndrome was defined as evidence of CMV in blood by viral isolation, rapid culture, antigenemia, or nucleic acid testing, and two or more of the following: fever ≥38°C for at least 2 days, new or increased malaise/fatigue, leukopenia or neutropenia on two separate measurements at least 24 hours apart, ≥5% atypical lymphocytes, thrombocytopenia, elevation of ALT or AST to 2x ULN.</p> <p><sup>†</sup> The 95% CIs for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (use/nonuse of highly cytolytic, anti-lymphocyte immunotherapy during induction).</p> <p><sup>‡</sup> Based on a non-inferiority margin of 10%, PREVYMIS® is non-inferior to valganciclovir. Approach to handling missing values: Observed Failure (OF) approach. With OF approach, subjects who discontinued prematurely from the study for any reason are not considered failures.</p> <p>N = number of subjects in each treatment group. n (%) = number (percent) of subjects in each sub-category.</p>		

Efficacy was comparable across all subgroups, including the use/nonuse of highly cytolytic, anti-lymphocyte immunotherapy during induction.

No subjects in the PREVMIS® group experienced CMV disease through Week 28 post-transplant compared with 5 subjects in the valganciclovir group.

## 15 MICROBIOLOGY

### Mechanism of Action

Letermovir inhibits the CMV DNA terminase complex, which is required for viral DNA replication. Biochemical characterization and electron microscopy demonstrated that letermovir affects the formation of proper unit length genomes and interferes with virion maturation.

### Antiviral Activity

The median EC<sub>50</sub> value of letermovir against a collection of clinical CMV isolates in a cell-culture model of infection was 2.1 nM (range = 0.7 nM to 6.1 nM, n = 74). There was no significant difference in EC<sub>50</sub> value by CMV gB genotype (n=70).

### Viral Resistance

#### *In Cell Culture*

The CMV genes UL51, UL56, and UL89 encode subunits of CMV DNA terminase. CMV mutants with reduced susceptibility to letermovir have been selected in cell culture, and the substitutions map to pUL51 (P91S, A95V), pUL56 (C25F, S229F, V231A, V231L, N232Y, V236A, V236L, V236M, E237D, L241P, T244K, T244R, L254F, L257F, L257I, K258E, F261C, F261L, F261S, Y321C, C325F, C325R, C325W, C325Y, L328V, M329T, A365S, N368D, R369G, R369M, R369S), and pUL89 (N320H, D344E). EC<sub>50</sub> values for recombinant CMV mutants expressing these substitutions are 1.6- to 9300-fold higher than those for the wild-type reference virus. EC<sub>50</sub> ratios of >3000 are interpreted as absolute letermovir resistance, because viral yield reduction occurs at visibly cytotoxic letermovir concentrations.

#### *In Clinical Studies*

In a Phase 2b trial evaluating letermovir doses of 60, 120, or 240 mg/day or placebo for up to 84 days in 131 HSCT recipients, DNA sequence analysis of a select region of UL56 (amino acids 231 to 369) was performed on samples obtained from 12 letermovir-treated subjects who experienced prophylaxis failure and for whom samples were available for analysis. One subject (who received 60 mg/day) had a letermovir resistant genotypic variant (GV) (V236M).

In a Phase 3 trial (P001), DNA sequence analysis of the entire coding regions of UL56 and UL89 was performed on samples obtained from 50 letermovir-treated subjects who experienced prophylaxis failure and for whom samples were available for analysis. A total of 4 letermovir resistance-associated substitutions all mapping to pUL56 were detected in 3 subjects as follows: V236M, C325W and R369T, and E237G, respectively.

In a Phase 3 trial (P002), DNA sequence analysis of the entire coding regions of UL51, UL56 and UL89 was performed on samples obtained from 52 letermovir-treated subjects who experienced CMV disease or who discontinued early with CMV viremia. There were no letermovir resistance-associated substitutions detected above the validated assay limit of 5%.

### Cross Resistance

Cross resistance is not likely with drugs outside of this class. Letermovir is fully active against viral populations with substitutions conferring resistance to CMV DNA polymerase inhibitors (ganciclovir, cidofovir, and foscarnet). A panel of recombinant CMV strains with substitutions conferring resistance

to letermovir was fully susceptible to cidofovir, foscarnet and ganciclovir with the exception of a recombinant strain with the pUL56 E237G substitution which confers a 2.1-fold reduction in ganciclovir susceptibility relative to wild-type.

## 16 NON-CLINICAL TOXICOLOGY

**General Toxicology:** Testicular toxicity was noted only in rats at systemic exposures (AUC)  $\geq$ 3-fold the exposures in humans at the recommended human dose (RHD). This toxicity was characterized by seminiferous tubular degeneration, and oligospermia and cell debris in the epididymides, with decreased testicular and epididymides weights. The No-Observed Adverse Effect Level (NOAEL) for testicular toxicity in rats was observed at exposures (AUC) in rats similar to the exposures in humans at the RHD. This testicular toxicity appears to be species-specific; testicular toxicity was not observed in mice and monkeys at the highest doses tested at exposures up to 4-fold and 2-fold, respectively, the exposures in humans at the RHD. The relevance to humans is unknown (see [8.3 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data](#)).

**Carcinogenicity:** A 6-month oral carcinogenicity study in rasH2 transgenic (Tg.rasH2) mice showed no evidence of human-relevant tumorigenesis up to the highest doses tested, 150 mg/kg/day (approximately the same AUC in humans at the RHD) and 300 mg/kg/day (approximately 2-fold the AUC in humans at the RHD) in males and females, respectively.

**Genotoxicity:** Letermovir was not genotoxic in a battery of *in vitro* or *in vivo* assays, including microbial mutagenesis assays, chromosomal aberration in Chinese Hamster Ovary cells, and in an *in vivo* mouse micronucleus study.

### **Reproductive and Developmental Toxicology:**

#### Reproduction

In the fertility and early embryonic development studies in the rat, there were no effects of letermovir on female fertility at the highest dose tested, 240 mg/kg/day (approximately 5-fold the AUC in humans at the RHD). In male rats, reduced sperm concentration, reduced sperm motility, and decreased fertility were observed at systemic exposures  $\geq$  3-fold the AUC in humans at the RHD (see [General Toxicity](#)).

#### Development

In pregnant rats, maternal toxicity (including decrease in body weight gain) was noted at the highest dose of 250 mg/kg/day (approximately 11-fold the AUC at the RHD); in the offspring, decreased fetal weight with delayed ossification, slightly edematous fetuses, and increased incidence of shortened umbilical cords and of variations and malformations in the vertebrae, ribs, and pelvis were observed. No maternal or developmental effects were noted up to the dose of 50 mg/kg/day (approximately 2.5-fold the AUC at the RHD).

In pregnant rabbits, maternal toxicity (including mortality and abortions) was noted at the highest dose of 225 mg/kg/day (approximately 2-fold the AUC at the RHD); in the offspring, an increased incidence of malformations and variations in the vertebrae and ribs were observed. No maternal or developmental effects were noted up to the dose of 75 mg/kg/day (at less than the AUC at the RHD).

In the pre- and post-natal developmental study, no developmental toxicity was observed up to the highest exposure of 180 mg/kg/day (2-fold the AUC at the RHD).



### Lactation

No effects of letermovir on growth and postnatal development were observed in nursing rat pups at the highest dose tested (at 2-fold the AUC at the RHD) (see [7.1 Special Populations, Pregnant Women](#)).